{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:06:23Z","timestamp":1790651183244,"version":"4.1.0"},"reference-count":60,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The 2022\u20132024 mpox outbreak in Europe was dominated by MPXV Clade IIb and generally mild, but recent Clade I\/Ib detections and early local transmission have changed preparedness needs. We performed a PRISMA-ScR scoping review of European mpox evidence from 2022 to 2026, supplemented by global and African data where regional evidence was sparse, covering clades, host determinants of severe disease, and antiviral efficacy and resistance, and ranking the evidence gaps. European Clade IIb surveillance showed very low mortality (10 deaths among 22,662 cases; case fatality 0.04%), contrasting with 3\u201311% estimates for Clade I\/Ib in affected African settings, although comparisons are confounded by age, health-system access and comorbidity. Severe European disease was driven mainly by immune compromise: non-HIV immunosuppression, uncontrolled HIV and CD4 counts &lt; 200 cells\/\u00b5L were the most consistent markers, while women were a small minority of cases, with higher hospitalisation risk, especially in pregnancy. Tecovirimat failed to improve outcomes in four randomised trials, F13L-associated resistance was reported in advanced HIV, and its European mpox use was subsequently restricted. The evidence base is strongest for mild Clade IIb infection in immunocompetent adults and weakest for the groups most likely to need treatment. Preparedness should prioritise harmonised genomic surveillance, severity-stratified cohort data and adaptive therapeutic trials enrolling immunocompromised, paediatric, pregnant and older patients.<\/jats:p>","DOI":"10.3390\/v18080865","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:12:01Z","timestamp":1786097521000},"page":"865","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mpox in Europe, 2022\u20132026: A Scoping Review of Viral Clades, Host Determinants of Severity and Antiviral Therapy"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5036-2120","authenticated-orcid":false,"given":"Filippos","family":"Sofos","sequence":"first","affiliation":[{"name":"Institute for Advanced Modelling and Simulation, University of Nicosia, Nicosia CY-2417, Cyprus"},{"name":"Condensed Matter Physics Laboratory, Department of Physics, University of Thessaly, 35100 Lamia, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5893-1081","authenticated-orcid":false,"given":"Zoi D.","family":"Pana","sequence":"additional","affiliation":[{"name":"Department of Basic and Clinical Studies, University of Nicosia Medical School, Nicosia CY-2408, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-7669","authenticated-orcid":false,"given":"Dimitris","family":"Drikakis","sequence":"additional","affiliation":[{"name":"Institute for Advanced Modelling and Simulation, University of Nicosia, Nicosia CY-2417, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e2489","DOI":"10.1002\/rmv.2489","article-title":"The 2022 monkeypox outbreak 1 year on: The 5 Ws","volume":"34","author":"Khan","year":"2024","journal-title":"Rev. Med. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3201\/eid3101.241230","article-title":"The Rise of Mpox in a Post-Smallpox World","volume":"31","author":"McQuiston","year":"2025","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100100","DOI":"10.1016\/j.soh.2024.100100","article-title":"Mpox (monkeypox): A comprehensive update of current epidemic evidence","volume":"4","author":"Hosain","year":"2025","journal-title":"Sci. One Health"},{"key":"ref_4","unstructured":"European Centre for Disease Prevention and Control (2024). Risk Assessment for the EU\/EEA of the Mpox Epidemic Caused by Monkeypox Virus Clade I in Affected African Countries, Technical Report."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11262-025-02138-2","article-title":"Phylogenetic analyses of the spread of Clade I MPOX in African and non-African nations","volume":"61","author":"Chakraborty","year":"2025","journal-title":"Virus Genes"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"04061","DOI":"10.7189\/jogh.15.04061","article-title":"Global epidemiology, viral evolution, and public health responses: A systematic review on Mpox (1958\u20132024)","volume":"15","author":"Jadhav","year":"2025","journal-title":"J. Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2400330","DOI":"10.2807\/1560-7917.ES.2024.29.27.2400330","article-title":"Continued circulation of mpox: An epidemiological and phylogenetic assessment, European Region, 2023 to 2024","volume":"29","author":"Vaughan","year":"2024","journal-title":"Eurosurveillance"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e1012","DOI":"10.1016\/S2214-109X(23)00198-5","article-title":"Description of the first global outbreak of mpox: An analysis of global surveillance data","volume":"11","author":"Hoxha","year":"2023","journal-title":"Lancet Glob. Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/hiv.13378","article-title":"Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany","volume":"24","author":"Hoffmann","year":"2023","journal-title":"HIV Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105289","DOI":"10.1016\/j.ebiom.2024.105289","article-title":"Clinical and laboratory predictors of mpox severity and duration: An Italian multicentre cohort study (mpox-ICONA)","volume":"107","author":"Mazzotta","year":"2024","journal-title":"eBioMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102402","DOI":"10.1016\/j.tmaid.2022.102402","article-title":"Phylogenomic analysis of the monkeypox virus (MPXV) 2022 outbreak: Emergence of a novel viral lineage?","volume":"49","author":"Luna","year":"2022","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e28853","DOI":"10.1002\/jmv.28853","article-title":"Genomic diversity of mpox virus in Paris area (France) during the 2022 outbreak","volume":"95","author":"Piorkowski","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/cid\/ciae657","article-title":"Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC)","volume":"80","author":"Pesonel","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/j.jinf.2022.08.019","article-title":"Natural history of human Monkeypox in individuals attending a sexual health clinic in Milan, Italy","volume":"86","author":"Moschese","year":"2023","journal-title":"J. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jinf.2023.04.001","article-title":"Viral bloodstream detection in mpox patients: An observational multicentric study","volume":"87","author":"Rizzo","year":"2023","journal-title":"J. Infect."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Catalano, G., Clemente, T., Diotallevi, S., Lolatto, R., Trentacapilli, B., Ranzenigo, M., Bruzzesi, E., Cinque, P., Castagna, A., and Nozza, S. (2025). Prevalence of Sexually Transmitted Infections Among Cisgender Women Coming to a Walk-In Center. Viruses, 17.","DOI":"10.3390\/v17040498"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/QAD.0000000000004225","article-title":"Sexually transmitted infections in MSM with tenofovir\/emtricitabine-resistant or cabotegravir-resistant HIV","volume":"39","author":"Clemente","year":"2025","journal-title":"AIDS"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103089","DOI":"10.1016\/j.aprim.2024.103089","article-title":"Mpox cases finding: Evaluation of a Primary Care detection program in the Northern Metropolitan area from Barcelona (Spain)","volume":"57","author":"Valerio","year":"2025","journal-title":"Atenci\u00f3n Primaria"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/cid\/ciad645","article-title":"Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study","volume":"78","author":"Hernando","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","first-page":"e108","article-title":"Immune responses associated with mpox viral clearance in men with and without HIV in Spain: A multisite, observational, prospective cohort study","volume":"5","author":"Benet","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Iguacel, R., Pericas, C., Bruguera, A., Rosell, G., Martinez, E., Diaz, Y., Alonso, L., Nomah, D.K., Blanco, J.L., and Domingo, P. (2023). Mpox: Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study. Microorganisms, 11.","DOI":"10.20944\/preprints202309.0225.v1"},{"key":"ref_22","first-page":"e29317","article-title":"Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination","volume":"96","author":"Du","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107132","DOI":"10.1016\/j.ijid.2024.107132","article-title":"Potential determinants of the decline in mpox cases in Belgium: A behavioral, epidemiological and seroprevalence study","volume":"146","author":"Brosius","year":"2024","journal-title":"Int. J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1473-3099(25)00545-6","article-title":"Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): A 24-month prospective and retrospective cohort study","volume":"26","author":"Zaeck","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Svartstein, A.S.W., Knudsen, A.D., Heidari, S.L., Hefdal, L.D., Gelpi, M., Benfield, T., and Nielsen, S.D. (2023). Mpox Incidence and Vaccine Uptake in Men Who Have Sex with Men and Are Living with HIV in Denmark. Vaccines, 11.","DOI":"10.3390\/vaccines11071167"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e29172","DOI":"10.1002\/jmv.29172","article-title":"Comparison of clinical course of Mpox among HIV-negative and HIV-positive patients: A 2022 cohort of hospitalised patients in Central Europe","volume":"95","author":"Kowalski","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10096-025-05346-8","article-title":"An atypical case of infection with the Mpox virus clade IIb lineage C.1\u2013Clinical and virological findings","volume":"45","author":"Zmora","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1017\/S0950268824000864","article-title":"Mpox in UK households: Estimating secondary attack rates and factors associated with transmission, May\u2013November 2022","volume":"152","author":"Packer","year":"2024","journal-title":"Epidemiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101045","DOI":"10.1016\/j.lanmic.2024.101045","article-title":"Immunogenicity of MVA-BN vaccine deployed as mpox prophylaxis: A prospective, single-centre, cohort study and analysis of transcriptomic predictors of response","volume":"6","author":"Drennan","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1038\/s41467-025-59370-5","article-title":"T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination","volume":"16","author":"Chen","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Karagiannis, I., Pires, J., le Polain de Waroux, O., Hoorelbeke, B., Gagni\u00e8re, B., Jansen, K., Tsiara, C., Igoes, D., Campitiello, M.R., and van Ewijk, C. (2025). Epidemiology and Characteristics of MPXV Clade I Cases in the WHO European Region, 2024\u20132025. medRxiv.","DOI":"10.64898\/2025.12.17.25342473"},{"key":"ref_32","unstructured":"European Centre for Disease Prevention and Control (2026). Communicable Disease Threats Report, Week 13, 22\u201328 March 2026, Update on Monkeypox Virus (MPXV) Clade I Cases in the EU\/EEA."},{"key":"ref_33","unstructured":"European Centre for Disease Prevention and Control (2026). Communicable Disease Threats Report, Week 26, 2026\u2013Section 6: Mpox in the EU\/EEA, Western Balkans and T\u00fcrkiye, Document 2026-WCP-0036."},{"key":"ref_34","unstructured":"European Centre for Disease Prevention and Control (2025). Threat Assessment Brief: Implications for the EU\/EEA of the Ongoing Mpox Outbreak."},{"key":"ref_35","unstructured":"UK Health Security Agency (2026). Mpox (Monkeypox) Clade Ib in England: Technical Briefing, April 2026, Technical Briefing, Cumulative Confirmed Clade Ib Cases Up to 30 April 2026, Including Secondary Transmission Events."},{"key":"ref_36","unstructured":"World Health Organization (2025). Statement of the WHO Director-General on the Determination That the Upsurge of Mpox no Longer Constitutes a Public Health Emergency of International Concern, WHO."},{"key":"ref_37","unstructured":"World Health Organization (2025). IHR (2005) Standing Recommendations for mpox, extended through August 2026. Standing Recommendations Issued Under the International Health Regulations (2005), WHO."},{"key":"ref_38","unstructured":"European Centre for Disease Prevention and Control (2026). Factsheet for Health Professionals on Mpox, Technical Report."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"PALM007 Writing Group (2025). Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo. N. Engl. J. Med., 392, 1484\u20131496.","DOI":"10.1056\/NEJMoa2412439"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1056\/NEJMoa2506495","article-title":"Tecovirimat for the Treatment of Mpox","volume":"394","author":"Zucker","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_41","unstructured":"Grinsztejn, B., and Calmy, A. (2025, January 13\u201317). Efficacy and safety of tecovirimat for mpox: Primary results of the UNITY randomised, placebo-controlled trial. Proceedings of the 13th IAS Conference on HIV Science (IAS 2025), Kigali, Rwanda."},{"key":"ref_42","unstructured":"PLATINUM Trial Investigators (2026). PLATINUM-UK: A Randomised, Placebo-Controlled Trial of Tecovirimat for Mpox in the United Kingdom, University of Oxford."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.3201\/eid2912.231146","article-title":"Tecovirimat Resistance in Mpox Patients, United States, 2022\u20132023","volume":"29","author":"Smith","year":"2023","journal-title":"Emerg. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e00972-23","DOI":"10.1128\/aac.00972-23","article-title":"Community spread of a human monkeypox virus variant with a tecovirimat resistance-associated mutation","volume":"67","author":"Garrigues","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","unstructured":"European Medicines Agency (2026, January 23\u201326). EMA recommends restricting use of Tecovirimat SIGA. Proceedings of the CHMP Recommendation, Amsterdam, The Netherlands."},{"key":"ref_46","unstructured":"(2026, July 04). Cohort Coordination Board. Central Data Repository. Available online: https:\/\/cohortcoordinationboard.eu\/."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Aromataris, E., Lockwood, C., Porritt, K., Pilla, B., and Jordan, Z. (2024). Scoping Reviews (2020). JBI Manual for Evidence Synthesis, JBI.","DOI":"10.46658\/JBIMES-24-01"},{"key":"ref_49","unstructured":"(2026, June 08). PROSPERO\u2014International Prospective Register of Systematic Reviews. Scope Statement. Available online: https:\/\/www.crd.york.ac.uk\/prospero\/#aboutregpage."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hiv.70120","article-title":"Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025","volume":"27","author":"Ambrosioni","year":"2026","journal-title":"HIV Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/20477724.2025.2551507","article-title":"Global and regional mortality rate statistics of mpox (formerly monkeypox): A comprehensive systematic review and meta-analysis","volume":"119","author":"Vasudevan","year":"2025","journal-title":"Pathog. Glob. Health"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kassaw, A.B., Alem, A., Abebe, M.S., Tareke, A.A., Mankelkl, G., Gedefie, A., Assefa, E.M., Belete, M., Abdu, H., and Geto, Z. (2026). Hospitalization rate and patterns of clinical reasons among Mpox-confirmed cases: A systematic review and meta-analysis. BMC Infect. Dis., 26.","DOI":"10.1186\/s12879-026-12602-5"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cmi.2025.08.019","article-title":"Lessons from the European mpox outbreak: Strengthening cohort research for future pandemic preparedness","volume":"32","author":"Visentin","year":"2026","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Rubini, E., Trentin, M., Maffi, P., Aammar, B., Gaievskyi, S., Bahattab, A., Lamine, H., Kordi-Kaiser, M., Staub, K., and Ragazzoni, L. (2026). Challenges in healthcare facilities\u2019 response to past outbreaks: A systematic review of reviews. BMC Health Serv. Res., 26.","DOI":"10.1186\/s12913-025-13934-9"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"101232","DOI":"10.1016\/j.onehlt.2025.101232","article-title":"From forest to frontline: A comprehensive review of Mpox\u2019s global leap and viral evolution (2022\u20132024)","volume":"21","author":"Akhavan","year":"2025","journal-title":"One Health"},{"key":"ref_56","first-page":"84","article-title":"Monkeypox Among Patients on PrEP\u2013A Case Report","volume":"33","author":"Pete","year":"2025","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Baker, B., Baz Lomba, J.A., Bitilinyu-Bangoh, J., Bergl\u00f6f, A., Bombaywala, S., Calvert-Joshua, T., Kabor\u00e9, B., Kingpriest, P., Lang, T., and Levy, J.I. (2026). Project ODIN: Advancing environmental genomic surveillance for public health across sub-Saharan Africa. Lancet Microbe, 101426.","DOI":"10.1016\/j.lanmic.2026.101426"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Caldrer, S., Accordini, S., Domini, A., Gianesini, N., Matucci, A., Mori, A., Mazzi, C., Cordioli, M., Tacconelli, E., and Ronzoni, N. (2025). Early Diagnosis and Monitoring of Adaptive Immune Response in a Cohort of Mild Mpox Patients During the 2022 Wave. Microorganisms, 13.","DOI":"10.3390\/microorganisms13020355"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Petruccioli, E., Sbarra, S., Vita, S., Salmi, A., Cuzzi, G., De Marco, P., Matusali, G., Navarra, A., Pierelli, L., and Grifoni, A. (2024). Characterization of the Monkeypox Virus (MPXV)-Specific Immune Response in MPXV-Cured Individuals Using Whole Blood to Monitor Memory Response. Vaccines, 12.","DOI":"10.3390\/vaccines12090964"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.vaccine.2023.12.086","article-title":"Genomic and transcriptomic analysis of the recent Mpox outbreak","volume":"42","author":"Giorgi","year":"2024","journal-title":"Vaccine"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/8\/865\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T10:14:39Z","timestamp":1786097679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/8\/865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["v18080865"],"URL":"https:\/\/doi.org\/10.3390\/v18080865","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}